Business Context and Reporting Period
Company: Compass Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 1, 2026
Reporting Period: Single event date (July 1, 2026)
This filing serves as a Regulation FD disclosure to update the company's corporate presentation. The update incorporates recent corporate developments, specifically data from the COMPANION-002 clinical study.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of non-financial corporate updates and does not contain audited or unaudited financial statements.
Material Changes
- Clinical Data Update: The company updated its corporate presentation to include data from the COMPANION-002 clinical study.
- Document Status: The updated presentation is furnished as Exhibit 99.1 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Guidance, Outlook, and Risks
Management Commentary: The filing references the inclusion of COMPANION-002 study data in the corporate presentation but does not provide specific management commentary, forward-looking guidance, or risk factors within the text of the 8-K itself. Investors must refer to Exhibit 99.1 for detailed study data and outlook.
Unusual Items: None reported in the filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation dated July 2026) for specific details on the COMPANION-002 clinical study data.
- Verify the clinical endpoints and statistical significance of the COMPANION-002 study results as presented in the exhibit.
- Confirm the regulatory implications of the new data for Compass Therapeutics' product pipeline.